In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vertex nets $313.6mm to support hepatitis and CF candidates

Executive Summary

Vertex Pharmaceuticals netted $313.6mm through the follow-on public offering of 10mm common shares at $32 apiece. The company will use the proceeds to support development of its lead candidates telaprevir, in Phase III for hepatitis C, and VX770, in Phase II for cystic fibrosis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register